Penobscot Investment Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Penobscot Investment Management’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.74M	Hold	19,450	–	–	0.12%	135
2026 Q1	$1.54M	Hold	19,450	–	–	0.12%	141
2025 Q4	$1.6M	Hold	19,450	–	–	0.12%	139
2025 Q3	$1.36M	Hold	19,450	–	–	0.1%	148
2025 Q2	$1.25M	Hold	19,450	–	–	0.11%	154
2025 Q1	$1.23M	Hold	19,450	–	–	0.12%	147
2024 Q4	$1.29M	Buy	19,450 +450	+2%	+$31K	0.12%	143
2024 Q3	$1.39M	Sell	19,000 -900	-5%	-$62.3K	0.12%	144
2024 Q2	$1.29M	Buy	19,900 +8,000	+67%	+$507K	0.12%	141
2024 Q1	$770K	Buy	11,900 +750	+7%	+$48.8K	0.08%	170
2023 Q4	$734K	Buy	11,150 +1,300	+13%	+$75.6K	0.09%	169
2023 Q3	$562K	Buy	+9,850	New	+$601K	0.08%	172

Other funds holding PBE

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.75B AUM 28.61% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Penobscot Investment Management's PBE Position: Q2 2026 in Review

Penobscot Investment Management held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q2 2026 at 19,450 shares worth $1.74M. The position accounts for 0.12% of the portfolio, ranked #135.

Penobscot Investment Management first reported a position in PBE in Q3 2023 and has held it in 12 quarters since. 105 funds tracked by Wall St. Rank hold PBE as of Q2 2026.

Penobscot Investment Management held 19,450 shares of Invesco Biotechnology & Genome ETF worth $1.74M as of Q2 2026.
Penobscot Investment Management left its Invesco Biotechnology & Genome ETF share count unchanged in Q2 2026.
Invesco Biotechnology & Genome ETF made up 0.12% of Penobscot Investment Management's portfolio in Q2 2026, its #135 holding.
Penobscot Investment Management first reported a position in Invesco Biotechnology & Genome ETF in Q3 2023 and has held it in 12 quarters since.
105 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2026.

Based on Penobscot Investment Management's 13F filing for Q2 2026, filed 24 Jul 2026.